Lymphoma Follow-Up Using PET Imaging

PET imaging was effective in identifying relapse in patients who were in complete remission.

Lymphoma patients who attain complete remission (CR) after induction therapy are routinely monitored for relapse with clinical evaluations, laboratory analysis, and computed tomography (CT) imaging studies. Molecular imaging with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET) has shown sensitivity in detecting disease in patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), but its role as a monitoring technique has not been defined.

Now, investigators have conducted a prospective trial of FDG-PET involving 421 lymphoma patients who achieved first CR, including 160 with HL, 183 with aggressive NHL, and 78 with indolent NHL. FDG-PET imaging was performed every 6 months for 2 years and then annually. Inconclusive …

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee